GlassScriptPhysician profile
Roula Younes
NPI 1760929897
$4,170.32
in general payments reported to CMS, 2019-2025
27 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $419 · 2022: $1,199 · 2023: $1,338 · 2024: $774 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $481.33 | 2021-2024 | |
| Janssen Biotech, INC. | $438.60 | 2022-2023 | Symtuza |
| Cumberland Pharmaceuticals, INC. | $394.24 | 2021-2024 | Vibativ |
| Paratek Pharmaceuticals, INC. | $363.08 | 2022-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $335.31 | 2021-2024 | Xerava |
| Insmed, INC. | $282.61 | 2021-2025 | Arikayce, Brinsupri |
| Astellas Pharma US INC | $242.84 | 2023-2024 | Cresemba |
| Merck Sharp & Dohme LLC | $234.10 | 2022-2024 | Dificid, Zerbaxa, Pifeltro |
| Intuitive Surgical, INC. | $144.60 | 2022 | |
| Shionogi INC | $130.59 | 2023-2025 | Fetroja |
| Nevro Corp. | $124.78 | 2022 | |
| Csl Behring | $123.35 | 2025 | Hizentra |
| Amgen INC. | $123.13 | 2024 | Krystexxa |
| Viiv Healthcare Company | $112.91 | 2021-2023 | Apretude |
| Smith+Nephew, INC. | $97.02 | 2022-2023 | Grafix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $93.66 | 2023 | Ams 700 |
| Theratechnologies INC. | $81.62 | 2023-2024 | Trogarzo, Egrifta |
| Abbott Laboratories | $73.18 | 2024 | Proclaim |
| Janssen Products, LP | $49.95 | 2021 | |
| Organogenesis INC. | $49.10 | 2024 | |
| Melinta Therapeutics, LLC | $45.58 | 2022 | |
| Aimmune Therapeutics, INC. | $37.50 | 2023 | |
| Kci USA, INC. | $24.14 | 2022 | |
| Mimedx Group, INC. | $23.66 | 2024 | |
| Napo Pharmaceuticals INC | $22.70 | 2025 | Mytesi |
| Pfizer INC. | $20.77 | 2023 | |
| Gilead Sciences, INC. | $19.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roula Younes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.